Prognostic significance of the systemic inflammation response index in gastrointestinal malignancy patients: a pooled analysis of 10,091 participants

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
  MedlineGoogle Scholar
• 2. Arnold M, Abnet CC, Neale RE et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology 159(1), 335–349 (2020).
  MedlineGoogle Scholar
• 3. Chen F, Xie C, Ren K, Xu X. Prognostic value of the Naples Prognostic Score in patients with gastrointestinal cancers: a meta-analysis. Nutr. Cancer 75(7), 1–11 (2023).
  MedlineGoogle Scholar
• 4. Atasever Akkas E, Erdis E, Yucel B. Prognostic value of the systemic immune-inflammation index, systemic inflammation response index, and prognostic nutritional index in head and neck cancer. Eur. Arch. Otorhinolaryngol. 280(8), 3821–3830 (2023).
  MedlineGoogle Scholar
• 5. Pang H, Zhang W, Liang X et al. Prognostic score system using preoperative inflammatory, nutritional and tumor markers to predict prognosis for gastric cancer: a two-center cohort study. Adv. Ther. 38(9), 4917–4934 (2021).
  MedlineGoogle Scholar
• 6. Zhao X, Zhou Y, Liu B et al. Preoperative neutrophil–lymphocyte ratio (NLR)–binding fibrinogen–albumin ratio (FAR) is superior to platelet–lymphocyte ratio (PLR)–binding fibrinogen–albumin ratio (FAR) and lymphocyte–monocyte (LMR)–binding fibrinogen–albumin ratio (FAR) as predictors of survival in surgical patients with colorectal adenocarcinoma. Med. Sci. Monit. 29, e939442 (2023).
  MedlineGoogle Scholar
• 7. Liu S, Li Z, Guo W, Fan Y. Predictive value of the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and monocyte-to-lymphocyte ratio esophageal stricture after endoscopic submucosal dissection of early esophageal cancer. Med. Sci. Monit. 29, e940041 (2023).
  MedlineGoogle Scholar
• 8. Li B, Zhou P, Liu Y et al. Platelet-to-lymphocyte ratio in advanced cancer: review and meta-analysis. Clin. Chim. Acta 483, 48–56 (2018).
  Medline CASGoogle Scholar
• 9. Chen L, Chen Y, Zhang L et al. In gastric cancer patients receiving neoadjuvant chemotherapy systemic inflammation response index is a useful prognostic indicator. Pathol. Oncol. Res. 27, 1609811 (2021).
  MedlineGoogle Scholar
• 10. Chu Y, Liu Y, Jiang Y et al. Prognosis and complications of patients with primary gastrointestinal diffuse large B-cell lymphoma: development and validation of the systemic inflammation response index-covered score. Cancer Med. 12(8), 9570–9582 (2023). • Recent retrospective study exploring the prognostic value of the systemic inflammation response index (SIRI) in gastrointestinal malignancy.
  Medline CASGoogle Scholar
• 11. Cao Y, Zheng X, Hu Y et al. Levels of systemic inflammation response index are correlated with tumor-associated bacteria in colorectal cancer. Cell Death Dis. 14(1), 69 (2023). •• Reported a superior prognostic predictability of the SIRI when compared with other simple biomarkers, such as neutrophil-to-lymphocyte, monocyte-to-lymphocyte and platelet-to-lymphocyte ratios.
  Medline CASGoogle Scholar
• 12. Chen Y, Jin M, Shao Y, Xu G. Prognostic value of the systemic inflammation response index in patients with adenocarcinoma of the oesophagogastric junction: a propensity score-matched analysis. Dis. Markers 2019, 4659048 (2019).
  MedlineGoogle Scholar
• 13. Qi Q, Zhuang L, Shen Y et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer 122(14), 2158–2167 (2016). •• The first study that developed the novel inflammatory biomarker SIRI.
  MedlineGoogle Scholar
• 14. Zheng Y, Chen Y, Chen J et al. Combination of systemic inflammation response index and platelet-to-lymphocyte ratio as a novel prognostic marker of upper tract urothelial carcinoma after radical nephroureterectomy. Front. Oncol. 9, 914 (2019).
  MedlineGoogle Scholar
• 15. Hu M, Xu Q, Yang S et al. Pretreatment systemic inflammation response index (SIRI) is an independent predictor of survival in unresectable stage III non-small cell lung cancer treated with chemoradiotherapy: a two-center retrospective study. Ann. Transl. Med. 8(20), 1310 (2020).
  MedlineGoogle Scholar
• 16. Valero C, Pardo L, Sansa A et al. Prognostic capacity of systemic inflammation response index (SIRI) in patients with head and neck squamous cell carcinoma. Head Neck 42(2), 336–343 (2020).
  MedlineGoogle Scholar
• 17. Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021).
  MedlineGoogle Scholar
• 18. Lin Y, Liu Z, Qiu Y et al. Clinical significance of plasma D-dimer and fibrinogen in digestive cancer: a systematic review and meta-analysis. Eur. J. Surg. Oncol. 44(10), 1494–1503 (2018). • Guideline for literature quality assessment.
  MedlineGoogle Scholar
• 19. Pang HY, Yan MH, Chen LH et al. Detection of asymptomatic recurrence following curative surgery improves survival in patients with gastric cancer: a systematic review and meta-analysis. Front. Oncol. 12, 1011683 (2022).
  MedlineGoogle Scholar
• 20. Yang XC, Liu H, Liu DC et al. Prognostic value of pan-immune-inflammation value in colorectal cancer patients: a systematic review and meta-analysis. Front. Oncol. 12, 1036890 (2022).
  Medline CASGoogle Scholar
• 21. Tierney JF, Stewart LA, Ghersi D et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8, 16 (2007). • Guideline for incorporating summary survival data into meta-analysis.
  MedlineGoogle Scholar
• 22. Cui S, Cao S, Chen Q et al. Preoperative systemic inflammatory response index predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation. Front. Immunol. 14, 1118053 (2023).
  Medline CASGoogle Scholar
• 23. Gao W, Zhang F, Ma T, Hao J. High preoperative fibrinogen and systemic inflammation response index (F-SIRI) predict unfavorable survival of resectable gastric cancer patients. J. Gastric Cancer 20(2), 202–211 (2020).
  MedlineGoogle Scholar
• 24. Geng Y, Zhu D, Wu C et al. A novel systemic inflammation response index (SIRI) for predicting postoperative survival of patients with esophageal squamous cell carcinoma. Int. Immunopharmacol. 65, 503–510 (2018).
  Medline CASGoogle Scholar
• 25. Jin B, Hu W, Su S et al. The prognostic value of systemic inflammation response index in cholangiocarcinoma patients. Cancer Manag. Res. 13, 6263–6277 (2021).
  MedlineGoogle Scholar
• 26. Kamposioras K, Papaxoinis G, Dawood M et al. Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapy. Acta Oncol. 61(5), 583–590 (2022).
  Medline CASGoogle Scholar
• 27. Kim JS, Choi M, Kim SH et al. Systemic inflammation response index correlates with survival and predicts oncological outcome of resected pancreatic cancer following neoadjuvant chemotherapy. Pancreatology 22(7), 987–993 (2022).
  Medline CASGoogle Scholar
• 28. Li Q, Zhang R, Fu JL et al. The prognostic value of preoperative peripheral blood inflammatory biomarkers for intrahepatic cholangiocarcinoma after radical resection. Zhonghua Zhong Liu Za Zhi 44(11), 1194–1201 (2022).
  Medline CASGoogle Scholar
• 29. Li S, Lan X, Gao H et al. Systemic inflammation response index (SIRI), cancer stem cells and survival of localised gastric adenocarcinoma after curative resection. J. Cancer Res. Clin. Oncol. 143(12), 2455–2468 (2017).
  Medline CASGoogle Scholar
• 30. Li S, Xu H, Wang W et al. The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma. Cancer Manag. Res. 11, 3327–3337 (2019).
  Medline CASGoogle Scholar
• 31. Li W, Peng QW, Lin Y et al. A model to predict the recurrence of middle–high risk gastrointestinal stromal tumors based on preoperative fibrinogen and peripheral blood inflammatory indexes. Zhonghua Wei Chang Wai Ke Za Zhi 23(9), 896–903 (2020).
  Medline CASGoogle Scholar
• 32. Liu Z, Ge H, Miao Z et al. Dynamic changes in the systemic inflammation response index predict the outcome of resectable gastric cancer patients. Front. Oncol. 11, 577043 (2021).
  MedlineGoogle Scholar
• 33. Pacheco-Barcia V, Mondéjar Solís R, France T et al. A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer. Pancreatology 20(2), 254–264 (2020).
  Medline CASGoogle Scholar
• 34. Qi WX, Wang X, Li C et al. Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: an analysis from a prospective cohort. Thorac. Cancer 14(17), 1556–1566 (2023).
  Medline CASGoogle Scholar
• 35. Sun L, Hu W, Liu M et al. High systemic inflammation response index (SIRI) indicates poor outcome in gallbladder cancer patients with surgical resection: a single institution experience in China. Cancer Res. Treat. 52(4), 1199–1210 (2020).
  MedlineGoogle Scholar
• 36. Topkan E, Selek U, Pehlivan B et al. The prognostic significance of novel pancreas cancer prognostic index in unresectable locally advanced pancreas cancers treated with definitive concurrent chemoradiotherapy. J. Inflamm. Res. 14, 4433–4444 (2021).
  MedlineGoogle Scholar
• 37. Wang SB, Chen JY, Xu C et al. Evaluation of systemic inflammatory and nutritional indexes in locally advanced gastric cancer treated with adjuvant chemoradiotherapy after D2 dissection. Front. Oncol. 12, 1040495 (2022).
  MedlineGoogle Scholar
• 38. Wang TC, An TZ, Li JX, Pang PF. Systemic inflammation response index is a prognostic risk factor in patients with hepatocellular carcinoma undergoing TACE. Risk Manag. Healthc. Policy 14, 2589–2600 (2021).
  MedlineGoogle Scholar
• 39. Wu Y, Tu C, Shao C. Inflammatory indexes in preoperative blood routine to predict early recurrence of hepatocellular carcinoma after curative hepatectomy. BMC Surg. 21(1), 178 (2021).
  Medline CASGoogle Scholar
• 40. Xin Y, Zhang X, Li Y et al. A systemic inflammation response index (SIRI)-based nomogram for predicting the recurrence of early stage hepatocellular carcinoma after radiofrequency ablation. Cardiovasc. Intervent. Radiol. 45(1), 43–53 (2022).
  MedlineGoogle Scholar
• 41. Xu L, Yu S, Zhuang L et al. Systemic inflammation response index (SIRI) predicts prognosis in hepatocellular carcinoma patients. Oncotarget 8(21), 34954–34960 (2017).
  MedlineGoogle Scholar
• 42. Yan K, Wei W, Shen W et al. Combining the systemic inflammation response index and prognostic nutritional index to predict the prognosis of locally advanced elderly esophageal squamous cell carcinoma patients undergoing definitive radiotherapy. J. Gastrointest. Oncol. 13(1), 13–25 (2022).
  MedlineGoogle Scholar
• 43. Yazici H, Yegen SC. Is systemic inflammatory response index (SIRI) a reliable tool for prognosis of gastric cancer patients without neoadjuvant therapy? Cureus 15(3), e36597 (2023).
  MedlineGoogle Scholar
• 44. Ying HQ, Liao YC, Sun F et al. The role of cancer-elicited inflammatory biomarkers in predicting early recurrence within stage II–III colorectal cancer patients after curable resection. J. Inflamm. Res. 14, 115–129 (2021).
  MedlineGoogle Scholar
• 45. Zhang J, Ding Y, Wang W et al. Combining the fibrinogen/albumin ratio and systemic inflammation response index predicts survival in resectable gastric cancer. Gastroenterol. Res. Pract. 2020, 3207345 (2020).
  MedlineGoogle Scholar
• 46. Zhao M, Duan X, Mi L et al. Prognosis of hepatocellular carcinoma and its association with immune cells using systemic inflammatory response index. Future Oncol. 18(18), 2269–2288 (2022).
  CASGoogle Scholar
• 47. Zhou Q, Su S, You W et al. Systemic inflammation response index as a prognostic marker in cancer patients: a systematic review and meta-analysis of 38 cohorts. Dose Response 19(4), 15593258211064744 (2021).
  Google Scholar
• 48. Khandia R, Munjal A. Interplay between inflammation and cancer. Adv. Protein Chem. Struct. Biol. 119, 199–245 (2020).
  Medline CASGoogle Scholar
• 49. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 454(7203), 436–444 (2008). •• Study exploring the relationship between inflammation and cancer.
  Medline CASGoogle Scholar
• 50. Tian BW, Yang YF, Yang CC et al. Systemic immune-inflammation index predicts prognosis of cancer immunotherapy: systemic review and meta-analysis. Immunotherapy 14(18), 1481–1496 (2022).
  CASGoogle Scholar
• 51. Ocana A, Nieto-Jiménez C, Pandiella A, Templeton AJ. Neutrophils in cancer: prognostic role and therapeutic strategies. Mol. Cancer 16(1), 137 (2017).
  MedlineGoogle Scholar
• 52. Xiong S, Dong L, Cheng L. Neutrophils in cancer carcinogenesis and metastasis. J. Hematol. Oncol. 14(1), 173 (2021).
  Medline CASGoogle Scholar
• 53. Jaillon S, Ponzetta A, Di Mitri D et al. Neutrophil diversity and plasticity in tumour progression and therapy. Nat. Rev. Cancer 20(9), 485–503 (2020).
  Medline CASGoogle Scholar
• 54. Mantovani A, Schioppa T, Porta C et al. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 25(3), 315–322 (2006).
  MedlineGoogle Scholar
• 55. Huang C, Li Z, Li N et al. Interleukin 35 expression correlates with microvessel density in pancreatic ductal adenocarcinoma, recruits monocytes, and promotes growth and angiogenesis of xenograft tumors in mice. Gastroenterology 154(3), 675–688 (2018).
  Medline CASGoogle Scholar
• 56. Ugel S, Canè S, De Sanctis F, Bronte V. Monocytes in the tumor microenvironment. Annu. Rev. Pathol. 16, 93–122 (2021).
  Medline CASGoogle Scholar
• 57. Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 32(19–20), 1267–1284 (2018).
  Medline CASGoogle Scholar
• 58. Wu ES, Oduyebo T, Cobb LP et al. Lymphopenia and its association with survival in patients with locally advanced cervical cancer. Gynecol. Oncol. 140(1), 76–82 (2016).
  MedlineGoogle Scholar